UBS AM’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $216M | Sell |
1,439,787
-183,724
| -11% | -$20M | 0.04% | 366 |
|
|
2026
Q1 | $150M | Sell |
1,623,511
-292,070
| -15% | -$29.3M | 0.03% | 433 |
|
|
2025
Q4 | $196M | Sell |
1,915,581
-346,288
| -15% | -$31M | 0.04% | 364 |
|
|
2025
Q3 | $141M | Sell |
2,261,869
-672,119
| -23% | -$36.6M | 0.03% | 415 |
|
|
2025
Q2 | $153M | Buy |
2,933,988
+156,948
| +6% | +$7.01M | 0.03% | 450 |
|
|
2025
Q1 | $118M | Buy |
2,777,040
+164,263
| +6% | +$7.09M | 0.03% | 495 |
|
|
2024
Q4 | $79.8M | Sell |
2,612,777
-731,260
| -22% | -$20.6M | 0.02% | 563 |
|
|
2024
Q3 | $76.7M | Buy |
3,344,037
+110,993
| +3% | +$3.14M | 0.02% | 580 |
|
|
2024
Q2 | $93.4M | Buy |
3,233,044
+2,331,011
| +258% | +$54.3M | 0.03% | 477 |
|
|
2024
Q1 | $18.6M | Buy |
902,033
+265,941
| +42% | +$5.7M | 0.01% | 807 |
|
|
2023
Q4 | $17.2M | Buy |
636,092
+49,643
| +8% | +$1.3M | 0.01% | 804 |
|
|
2023
Q3 | $17.4M | Buy |
586,449
+298,172
| +103% | +$10.5M | 0.01% | 792 |
|
|
2023
Q2 | $6.76M | Hold |
288,277
| – | – | ﹤0.01% | 1107 |
|
|
2023
Q1 | $6.76M | Buy |
288,277
+3,792
| +1% | +$108K | ﹤0.01% | 1107 |
|
|
2022
Q4 | $7.74M | Buy |
284,485
+146,794
| +107% | +$6.72M | ﹤0.01% | 1027 |
|
|
2022
Q3 | $7.41M | Sell |
137,691
-22,199
| -14% | -$1.14M | ﹤0.01% | 1061 |
|
|
2022
Q2 | $6.45M | Sell |
159,890
-81,259
| -34% | -$4.03M | ﹤0.01% | 1120 |
|
|
2022
Q1 | $16M | Sell |
241,149
-42,884
| -15% | -$2.93M | 0.01% | 909 |
|
|
2021
Q4 | $28.4M | Buy |
284,033
+37,780
| +15% | +$3.91M | 0.01% | 811 |
|
|
2021
Q3 | $30.8M | Buy |
246,253
+139,023
| +130% | +$16.5M | 0.01% | 755 |
|
|
2021
Q2 | $13.3M | Buy |
107,230
+5,692
| +6% | +$766K | 0.01% | 1014 |
|
|
2021
Q1 | $15.5M | Buy |
101,538
+561
| +0.6% | +$84.8K | 0.01% | 937 |
|
|
2020
Q4 | $13M | Buy |
100,977
+36,796
| +57% | +$4.23M | 0.01% | 963 |
|
|
2020
Q3 | $7.17M | Buy |
64,181
+402
| +0.6% | +$36.8K | ﹤0.01% | 1035 |
|
|
2020
Q2 | $5.17M | Buy |
63,779
+13,673
| +27% | +$1.1M | ﹤0.01% | 1105 |
|
|
2020
Q1 | $3.49M | Buy |
50,106
+11,757
| +31% | +$902K | ﹤0.01% | 1197 |
|
|
2019
Q4 | $3M | Sell |
38,349
-4,902
| -11% | -$353K | ﹤0.01% | 1431 |
|
|
2019
Q3 | $2.76M | Buy |
43,251
+19,718
| +84% | +$1.74M | ﹤0.01% | 1465 |
|
|
2019
Q2 | $2.03M | Buy |
+23,533
| New | +$1.8M | ﹤0.01% | 1583 |
|
Other funds holding GH
DTC
UBS AM's GH Position: Q2 2026 in Review
UBS AM reduced its Guardant Health (GH) stake by 11% in Q2 2026, selling an estimated $20M and leaving 1,439,787 shares worth $216M. The position accounts for 0.04% of the portfolio, ranked #366.
UBS AM first reported a position in GH in Q2 2019 and has held it in 29 quarters since. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- UBS AM held 1,439,787 shares of Guardant Health worth $216M as of Q2 2026.
- UBS AM sold 183,724 Guardant Health shares in Q2 2026, an estimated $20M.
- Guardant Health made up 0.04% of UBS AM's portfolio in Q2 2026, its #366 holding.
- UBS AM first reported a position in Guardant Health in Q2 2019 and has held it in 29 quarters since.
- 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.